![](https://investorshub.advfn.com/uicon/178446.png?cb=1467873950)
Tuesday, March 21, 2023 8:14:42 AM
https://www.accesswire.com/744839/Halberd-Eradicates-All-Strains-of-Antibiotic-Resistant-E-Coli-Provided-by-the-CDC-at-Youngstown-State-University
JACKSON CENTER, PA / ACCESSWIRE / March 21, 2023 / Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC. Using Halberd's patented extracorporeal (outside the body) process and patent-pending laser eradication method in conjunction with metallic nanoparticles, over 90% of each of the bacteria strains was eradicated in under 10 minutes of process time.
Halberd is currently testing antibiotic resistant Klebsiella pneumoniae strains at Youngstown State University (YSU) and expects to have the testing completed prior to the meeting with the CDC. According to the CDC, Klebsiella pneumoniae, a Gram-negative bacteria which has developed antibiotic resistance, can cause pneumonia, blood stream infections, wound or surgical site infections, and meningitis. Gram-negative bacteria are resistant to multiple drugs and are increasingly resistant to most available antibiotics.[1]
Dr. Chester Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "So far, we have been able to eradicate all of the antibiotic resistant E. coli strains provided and have also eradicated five strains of antibiotic resistant Candida auris fungus, and are confident that our methodology will be successful on Klebsiella strains."
Dr. W. Gregg Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department added, "With each test, we gain insights into how to improve the process and generate ideas on the best way to move this technology from the laboratory to a therapeutic application."
William A. Hartman, Halberd's Chairman, President & CEO commented, "What is astounding is that Halberd has been able to eradicate such a wide variety of pathogens in a matter of minutes, compared to days with a normal course of drug treatments. And since this procedure can be conducted outside the body, the potential for adverse side-effects is minimal to non-existent.
"Halberd has assembled an outstanding team of "Halberd Heroes" who have developed our great multi-use technology and deserve a salute for their dedication. The CDC may have supplied antibiotic-resistant pathogens to Halberd, but our team has proven that those pathogens are not Halberd-resistant."
![Bullish](/static/images/ih2-bull.png)
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM